DexCom, Inc. (NASDAQ:DXCM) Shares Purchased by Fifth Third Wealth Advisors LLC

Fifth Third Wealth Advisors LLC increased its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 305.4% during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 29,646 shares of the medical device company’s stock after buying an additional 22,334 shares during the period. Fifth Third Wealth Advisors LLC’s holdings in DexCom were worth $1,987,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Crewe Advisors LLC acquired a new stake in shares of DexCom during the 1st quarter valued at about $29,000. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in DexCom in the second quarter valued at approximately $25,000. Sachetta LLC increased its position in shares of DexCom by 255.2% in the second quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock valued at $27,000 after buying an additional 171 shares in the last quarter. DT Investment Partners LLC raised its stake in shares of DexCom by 492.2% during the 2nd quarter. DT Investment Partners LLC now owns 379 shares of the medical device company’s stock worth $43,000 after buying an additional 315 shares during the period. Finally, Riverview Trust Co lifted its position in shares of DexCom by 100.4% during the 3rd quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock valued at $31,000 after buying an additional 232 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently commented on DXCM. JPMorgan Chase & Co. boosted their price target on shares of DexCom from $75.00 to $85.00 and gave the stock a “neutral” rating in a report on Friday, October 25th. Sanford C. Bernstein upped their price target on shares of DexCom from $82.00 to $86.00 and gave the stock an “outperform” rating in a research report on Friday, October 25th. Wells Fargo & Company lifted their price objective on DexCom from $80.00 to $90.00 and gave the stock an “overweight” rating in a report on Friday, October 25th. UBS Group reduced their target price on DexCom from $163.00 to $95.00 and set a “buy” rating for the company in a report on Friday, July 26th. Finally, Raymond James lowered their price target on DexCom from $115.00 to $99.00 and set a “strong-buy” rating on the stock in a research note on Friday, October 25th. Seven equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $104.59.

DexCom Price Performance

Shares of DXCM stock opened at $74.88 on Wednesday. The firm’s 50-day moving average is $70.16 and its two-hundred day moving average is $90.82. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12. The company has a market capitalization of $29.25 billion, a PE ratio of 44.84, a price-to-earnings-growth ratio of 2.33 and a beta of 1.17.

Insider Activity

In related news, EVP Sadie Stern sold 426 shares of the firm’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $29,457.90. Following the completion of the sale, the executive vice president now directly owns 75,451 shares of the company’s stock, valued at approximately $5,217,436.65. This trade represents a 0.56 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Jacob Steven Leach sold 746 shares of the company’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the transaction, the chief operating officer now directly owns 264,915 shares in the company, valued at $18,318,872.25. The trade was a 0.28 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.30% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.